CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics Statistics
Share Statistics
CRISPR Therapeutics has 86.19M shares outstanding. The number of shares has increased by 1.01% in one year.
| Shares Outstanding | 86.19M |
| Shares Change (YoY) | 1.01% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 76.49% |
| Shares Floating | 82.46M |
| Failed to Deliver (FTD) Shares | 24.38K |
| FTD / Avg. Volume | 1.09% |
Short Selling Information
The latest short interest is 20.51M, so 23.91% of the outstanding shares have been sold short.
| Short Interest | 20.51M |
| Short % of Shares Out | 23.91% |
| Short % of Float | 27.08% |
| Short Ratio (days to cover) | 11.65 |
Valuation Ratios
The PE ratio is -9.07 and the forward PE ratio is -9.53. CRISPR Therapeutics's PEG ratio is -0.07.
| PE Ratio | -9.07 |
| Forward PE | -9.53 |
| PS Ratio | 94.87 |
| Forward PS | 1.3 |
| PB Ratio | 1.72 |
| P/FCF Ratio | -22.95 |
| PEG Ratio | -0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CRISPR Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.07, with a Debt / Equity ratio of 0.12.
| Current Ratio | 22.07 |
| Quick Ratio | 22.07 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.48 |
| Debt / FCF | -1.55 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $89.06K |
| Profits Per Employee | $-931.94K |
| Employee Count | 393 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 3.59M |
| Effective Tax Rate | -0.99% |
Stock Price Statistics
The stock price has increased by -27.25% in the last 52 weeks. The beta is 1.84, so CRISPR Therapeutics's price volatility has been higher than the market average.
| Beta | 1.84 |
| 52-Week Price Change | -27.25% |
| 50-Day Moving Average | 40.95 |
| 200-Day Moving Average | 45.79 |
| Relative Strength Index (RSI) | 53.36 |
| Average Volume (20 Days) | 2.24M |
Income Statement
In the last 12 months, CRISPR Therapeutics had revenue of 35M and earned -366.25M in profits. Earnings per share was -4.34.
| Revenue | 35M |
| Gross Profit | 37.31M |
| Operating Income | -466.57M |
| Net Income | -366.25M |
| EBITDA | -466.57M |
| EBIT | -466.57M |
| Earnings Per Share (EPS) | -4.34 |
Balance Sheet
The company has 298.26M in cash and 223.69M in debt, giving a net cash position of 74.56M.
| Cash & Cash Equivalents | 298.26M |
| Total Debt | 223.69M |
| Net Cash | 74.56M |
| Retained Earnings | -1.37B |
| Total Assets | 2.24B |
| Working Capital | 1.85B |
Cash Flow
In the last 12 months, operating cash flow was -142.77M and capital expenditures -1.9M, giving a free cash flow of -144.68M.
| Operating Cash Flow | -142.77M |
| Capital Expenditures | -1.9M |
| Free Cash Flow | -144.68M |
| FCF Per Share | -1.71 |
Margins
Gross margin is 106.61%, with operating and profit margins of -1333.05% and -1046.43%.
| Gross Margin | 106.61% |
| Operating Margin | -1333.05% |
| Pretax Margin | -1036.19% |
| Profit Margin | -1046.43% |
| EBITDA Margin | -1333.05% |
| EBIT Margin | -1333.05% |
| FCF Margin | -413.36% |
Dividends & Yields
CRSP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRSP is $82, which is 109.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $82 |
| Price Target Difference | 109.8% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
Scores
| Altman Z-Score | 5.78 |
| Piotroski F-Score | 3 |